Research programme: Alzheimer's disease therapeutics - Pfizer Centers for Therapeutic Innovation/Alzheimer's Drug Discovery Foundation

Drug Profile

Research programme: Alzheimer's disease therapeutics - Pfizer Centers for Therapeutic Innovation/Alzheimer's Drug Discovery Foundation

Latest Information Update: 14 Feb 2015

Price : $50

At a glance

  • Originator Alzheimers Drug Discovery Foundation; Pfizer Centers for Therapeutic Innovation
  • Developer Alzheimers Drug Discovery Foundation
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Alzheimer's disease

Most Recent Events

  • 11 Feb 2015 Early research in Alzheimer's disease in USA (unspecified route)
  • 11 Feb 2015 Pfizer Centers for Therapeutic Innovation and Alzheimer's Drug Discovery Foundation agree to co-develop drugs for Alzheimer's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top